Illinois is currently home to 2681 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Far Red Light to Improve Functioning in PAD
Recruiting
The LIGHT PAD Trial is a Phase II multi-centered randomized clinical trial to collect preliminary data to test whether daily far red light treatment of the lower extremities in people with PAD improves six-minute walk distance, lower extremity perfusion, and ischemia-related damage in gastrocnemius muscle at four-month follow-up, compared to a sham control. Participants will complete 10 minutes of twice daily home treatment with either far red light or a sham light for four months.
Gender:
All
Ages:
50 years and above
Trial Updated:
04/30/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Peripheral Artery Disease, Peripheral Vascular Disease, Aging, Walking, Difficulty
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Recruiting
CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Advanced Solid Tumor
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Recruiting
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Dr. Sudarshan K. Sharma, Ltd., Hinsdale, Illinois
Conditions: Endometrial Cancer
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
Recruiting
Doctors leading this study hope to learn about the safety of combining the study drug VS-6766 with another drug called cetuximab in colorectal cancer. This study is for individuals who have advanced colorectal cancer and their cancer has progressed while getting previous treatment or individuals who cannot take/tolerate previous treatments. If you choose to participate, your time in this research will last up to 24 months.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
The COCOA-PAD II Trial
Recruiting
Among people with peripheral artery disease (PAD) age 55 and older, the investigators will test the hypothesis that PAD participants randomized to cocoa flavanols will have greater improvement or less decline in six-minute walk distance at six-month follow-up, compared to those randomized to placebo. The study will randomize 190 participants with PAD age 55 and older to one of two groups for six months: cocoa flavanols vs placebo. Our primary outcome is change in six-minute walk distance at six-... Read More
Gender:
All
Ages:
55 years and above
Trial Updated:
04/30/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Peripheral Artery Disease
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Recruiting
This pilot clinical trial studies genetic analysis-guided irontecan hydrochloride dosing of modified fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin (mFOLFIRINOX) in treating patients with gastroesophageal or stomach cancer that has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Stage IIB Gastric Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Gastric Cancer
Connect® Myeloid Disease Registry
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Hektoen Inst for Medical Resrch on behalf of itself and John H Stroger Hosp, Chicago, Illinois
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science
Recruiting
The goal of this study is to identify genes that convey susceptibility to congenital diaphragmatic hernia in humans. The identification of such genes, and examination of their structure and function, will enable a delineation of molecular pathogenesis and, ultimately, prevention or treatment of congenital diaphragmatic hernia. There are many different possible modes of inheritance for congenital anomalies, including autosomal dominant, autosomal recessive, and multifactorial. Multi-factorial inh... Read More
Gender:
All
Ages:
All
Trial Updated:
04/30/2024
Locations: Rush Hospital, Chicago, Illinois
Conditions: Congenital Diaphragmatic Hernia
Reward and Drug Effects on Mood and Brain Response
Recruiting
The goal of the study is to better understand the neural mechanisms underlying the rewarding, reinforcing properties of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, among healthy young adults.
Gender:
All
Ages:
Between 18 years and 25 years
Trial Updated:
04/29/2024
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Cannabis Use, Healthy
Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction
Recruiting
Very little is understood about the off-target vascular mechanisms of anti-cancer drug toxicity and the impact of exercise on these changes. Much of what has been learned about molecular pathways regulating vascular endothelial function has been established by logical expansion of knowledge obtained through experimental studies (e.g., discovery of endothelium-derived relaxing factor/nitric oxide). Within the last 10 years technological advancements of -omics approaches, such as RNA-sequencing an... Read More
Gender:
Female
Ages:
Between 18 years and 100 years
Trial Updated:
04/28/2024
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Breast Cancer
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
Recruiting
This multi-site study is being conducted to examine dietary and activity patterns, body composition, blood and quality of life in breast cancer patients. The study will recruit 176 women with MBC in Milwaukee (n=88) and Chicago (n=88).
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/28/2024
Locations: Loyola University, Maywood, Illinois
Conditions: Metastatic Breast Cancer
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
Recruiting
Primary Objectives To assess the safety and tolerability of RGLS8429 To assess the impact of RGLS8429 on ADPKD biomarkers Secondary Objectives To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) To characterize the pharmacokinetic (PK) properties of RGLS8429 To assess the impact of RGLS8429 on renal function
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/27/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant